ClearPoint Neuro, Inc. (NASDAQ:CLPT) Short Interest Update

ClearPoint Neuro, Inc. (NASDAQ:CLPT) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totalling 1,280,000 shares, a decrease of 8.6% from the March 15th total of 1,400,000 shares. Based on an average daily trading volume, of 152,300 shares, the short-interest ratio is presently 8.4 days.

Analysts Set New Price Targets

Separately, Stifel Nicolaus restated a “buy” rating and set a $9.00 price target (up from $8.00) on shares of ClearPoint Neuro in a report on Wednesday, March 13th.

Institutional Investors Weigh In On ClearPoint Neuro

Institutional investors and hedge funds have recently bought and sold shares of the stock. Advisor Group Holdings Inc. raised its position in ClearPoint Neuro by 131.5% in the 1st quarter. Advisor Group Holdings Inc. now owns 2,153 shares of the company’s stock valued at $66,000 after buying an additional 1,223 shares during the last quarter. State of Wyoming purchased a new stake in ClearPoint Neuro in the 4th quarter valued at $25,000. Cubist Systematic Strategies LLC purchased a new stake in shares of ClearPoint Neuro during the 1st quarter valued at $38,000. Royal Bank of Canada increased its position in shares of ClearPoint Neuro by 3,038.5% during the 2nd quarter. Royal Bank of Canada now owns 5,461 shares of the company’s stock valued at $40,000 after purchasing an additional 5,287 shares during the last quarter. Finally, California State Teachers Retirement System purchased a new stake in shares of ClearPoint Neuro during the 2nd quarter valued at $55,000. 30.08% of the stock is owned by hedge funds and other institutional investors.

ClearPoint Neuro Stock Down 3.4 %

Shares of CLPT traded down $0.20 during trading hours on Monday, reaching $5.61. The stock had a trading volume of 304,735 shares, compared to its average volume of 150,603. ClearPoint Neuro has a 12 month low of $4.05 and a 12 month high of $10.80. The firm has a 50-day simple moving average of $6.79 and a 200 day simple moving average of $6.32. The company has a current ratio of 4.87, a quick ratio of 3.80 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $151.86 million, a price-to-earnings ratio of -6.16 and a beta of 0.89.

ClearPoint Neuro (NASDAQ:CLPT) last issued its earnings results on Tuesday, March 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03. ClearPoint Neuro had a negative return on equity of 83.94% and a negative net margin of 92.21%. The company had revenue of $6.81 million for the quarter, compared to analysts’ expectations of $6.40 million. Equities research analysts predict that ClearPoint Neuro will post -0.75 earnings per share for the current fiscal year.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.